Highest-materiality recent filing
Both director nominees re-elected: Rhonda Hellums (47.2M for, 5.6M against) and James Ede-Golightly (52.1M for, 0.6M against).
21 PV patients: 5 phlebotomies during active treatment vs 80 in prior 6 months; only 4 in 16-week follow-up.
Silence Therapeutics enters new ATM with Jefferies; says not PFIC for 2025
Entered at-the-market equity offering agreement with Jefferies LLC; prior 2021 ATM agreement terminated.
Silence Therapeutics Q1 net loss $15M; Phase 2 PV trial on track for August 2026 topline
Net loss of $15.0M ($0.11 per share) vs $28.5M ($0.20) a year ago; revenue from AstraZeneca collaboration $0.4M.
Silence Therapeutics FY 2025 net loss $88.6M; top-line divesiran data on-track for Q3 2026
Net loss widened to $88.6M ($0.63/share) from $45.3M ($0.33/share) in FY 2024.
Silence Therapeutics discloses interim CEO pay and new director committee roles
Interim CEO Iain Ross receives £25,000/month cash for six months, then month-to-month, plus 900,000 option shares vesting over 12 months.
Silence Therapeutics appoints CFO Rhonda Hellums to Board of Directors effective Dec 18, 2025
Rhonda Hellums, EVP and CFO, appointed as executive director effective December 18, 2025.
Craig Tooman stepped down as President, CEO and Board member effective Dec 14, 2025 by mutual consent.
Cash and investments $102.2M as of Sept 30, 2025, providing runway into 2028.
48 phlebotomy-dependent PV patients enrolled in global, randomized, double-blind, placebo-controlled study.
Director Michael Davidson resigns from Silence Therapeutics board
Davidson resigned as director effective August 11, 2025, citing need to focus on other time commitments.
Silence Therapeutics Q2 net loss widens to $27.4M; cash $114.2M, divesiran Phase 2 on track
Net loss of $27.4M in Q2 2025 vs $19.8M in Q2 2024; R&D expenses rose to $17.6M.
Silence Therapeutics shareholders approve all 13 AGM resolutions, re-elect directors
All directors re-elected: David Lemus (77.0M for), Tim McInerney (77.0M for), Iain Ross (74.8M for), Craig Tooman (78.2M for).
Silence Therapeutics Q1 net loss widens to $28.5M; cash runway extended into 2028
Cash and short-term investments $136.5M at Mar 31, 2025, down from $147.3M at Dec 31, 2024.
Silence Therapeutics appoints Tim McInerney to board; James Ede-Golightly to retire at June 2025 AGM
Tim McInerney appointed director effective May 5, 2025; will chair Remuneration Committee and join Audit and Risk Committee.
Silence Therapeutics extends cash runway into 2027; will require partner for zerlasiran Phase 3
Net loss of $45.3M ($0.33 per share) for FY2024, compared to $54.2M loss in FY2023.
Effective January 1, 2025, Silence Therapeutics (SLN) will file periodic reports on U.S. domestic issuer forms, no longer as a foreign private issuer.
On May 5, 2025, upon the recommendation of the Nominations Committee, the Board appointed Tim McInerney to serve as a director of the Company, effective immediately.
On May 5, 2025, James Ede-Golightly notified the board of directors (the “ Board ”) of Silence Therapeutics plc (the “ Company ”) of his decision to retire from the Board following the end of his current term, which expires at the end of the Company’s 2025 Annual General Meeting of Shareholders, which is anticipated to be held on June 26, 2025 (the “ 2025 AGM ”).
Max materiality 0.75 · Median 0.55 · Most common event earnings